化脓性汗腺炎患者总体及特定癌症风险评估
结果显示HS患者总体癌症风险显著升高(aHR 1.28),且霍奇金淋巴瘤、口腔咽喉癌、中枢神经系统癌、非黑色素瘤皮肤癌、前列腺癌和结直肠癌风险显著增加。
要点
- HS患者总体癌症风险较对照升高28%(aHR 1.28)。
- 特定癌症风险显著增加,包括霍奇金淋巴瘤、口腔咽喉癌、中枢神经系统癌、非黑色素瘤皮肤癌、前列腺癌和结直肠癌。
- 临床需关注HS患者癌症筛查,尤其针对上述特定癌种。
核心结论
- HS与总体癌症风险及多种特定癌症风险显著增加相关。
主要发现
- HS患者总体癌症调整风险比(aHR)为1.28(95%CI 1.15-1.42)。
- 霍奇金淋巴瘤aHR为5.08(95%CI 1.21-21.36)。
- 口腔咽喉癌aHR为3.10(95%CI 1.60-6.02)。
- 中枢神经系统癌aHR为2.40(95%CI 1.22-4.70)。
- 非黑色素瘤皮肤癌HR为2.06(95%CI 1.12-3.79),前列腺癌aHR为2.05(95%CI 1.30-3.24),结直肠癌aHR为1.45(95%CI 1.09-1.93)。
临床怎么用
- 对HS患者应提高癌症警觉,考虑针对性筛查和早期识别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Large population-based studies investigating the risks of overall and specific cancers among patients with hidradenitis suppurativa (HS) are limited. OBJECTIVE: To assess the overall and specific cancer risks in patients with HS compared with the risks in patients without HS in the Republic of Korea. DESIGN, SETTING, AND PARTICIPANTS: A nationwide population-based cohort study, using the Korean Health Insurance Review and Assessment Service database was conducted over a 2-year period from January 1, 2007, to December 31, 2008. Individuals in the control group who were never diagnosed with HS or cancer during the washout period were randomly extracted and matched by age, sex, index year, and insurance type at a case-control ratio of 1:8, and patients with newly diagnosed HS between January 1, 2009, and December 31, 2017, were included. Follow-up data on incident cancer from January 1, 2009, to December 31, 2018, were included. MAIN OUTCOMES AND MEASURES: The overall and specific cancer incidence rates were calculated per 100 000 person-years in patients with HS and in the matched control cohort. The risk for cancers was assessed by multivariable Cox regression models in patients with HS compared with the matched control cohort. RESULTS: In total, 22 468 patients with HS and 179 734 matched controls were included in the study. The mean (SD) age was 33.63 (17.61) years and 63.7% of the participants in both groups were male. The adjusted hazard ratio (aHR) of overall cancer in patients with HS was 1.28 (95% CI, 1.15-1.42). Patients with HS had significantly higher risk for Hodgkin lymphoma (aHR, 5.08; 95% CI, 1.21-21.36), oral cavity and pharyngeal cancer (aHR, 3.10; 95% CI, 1.60-6.02), central nervous system cancer (aHR, 2.40; 95% CI, 1.22-4.70), nonmelanoma skin cancer (HR, 2.06; 95% CI, 1.12-3.79), prostate cancer (aHR, 2.05; 95% CI, 1.30-3.24), and colorectal cancer (aHR, 1.45; 95% CI, 1.09-1.93). CONCLUSIONS AND RELEVANCE: In this study, HS appeared to be associated with a significantly increased risk of overall cancer as well as several specific cancers.
引用
- Jung JM, Lee KH, Kim YJ, et al. Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa. JAMA Dermatol. 2020. PMID: 32459291. doi:10.1001/jamadermatol.2020.1422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。